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Abstract
Vascular cell adhesion molecule-1 (VCAM-1) is strongly upregulated in hearts of mice with
coxsackie virus-induced as well as in patients with viral infection-triggered dilated cardiomy-
opathy. Nevertheless, the role of its soluble form as a biomarker in inflammatory heart dis-
eases remains unclear. Therefore, we investigated whether plasma levels of soluble
VCAM-1 (sVCAM-1) directly correlated with disease activity and progression of cardiac dys-
function in the mouse model of experimental autoimmune myocarditis (EAM). EAM was
induced by immunization of BALB/cmice with heart-specific myosin-alpha heavy chain
peptide together with complete Freund`s adjuvant. ELISA revealed strong expression of
cardiac VCAM-1 (cVCAM-1) throughout the course of EAM in immunized mice compared to
control animals. Furthermore, sVCAM-1 was elevated in the plasma of immunized com-
pared to control mice at acute and chronic stages of the disease. sVCAM-1 did not correlate
with the degree of acute cardiac inflammation analyzed by histology or cardiac cytokine
expression investigated by ELISA. Nevertheless, heart to body weight ratio correlated sig-
nificantly with sVCAM-1 at chronic stages of EAM. Cardiac systolic dysfunction studied with
positron emission tomography indicated a weak relationship with sVCAM-1 at the chronic
stage of the disease. Our data provide evidence that plasma levels of sVCAM-1 are ele-
vated throughout all stages of the disease but showed no strong correlation with the severity
of EAM.
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Introduction
Myocarditis denotes cardiac inflammation, which is often triggered by viral pathogens such as
adeno-, herpes-, coxsackie- or enterovirus.[1, 2] Despite the fact that myocarditis is self-limit-
ing in up to 40%,[3] ongoing autoimmune processes and/or persistent viral infections can lead
to chronic inflammation with subsequent dilation and dysfunction of the heart.[4] Although
substantial efforts have been made to understand the pathophysiologic mechanisms of acute
and chronic myocarditis, no established biomarker has been defined to reliably reveal the diag-
nosis and/or depict the severity of the disease at various stages.
Vascular cell adhesion molecule-1 (VCAM-1) is predominantly expressed on activated
endothelia during inflammation as a ligand for α1β4 integrins, mediating recruitment of leuko-
cytes.[5] Its soluble form, referred to as sVCAM-1, has been shown to correlate with disease
activity in various entities including rheumatoid arthritis (RA)[6] or systemic lupus erythema-
tosus (SLE)[7, 8] and predicts unfavourable outcome in patients with coronary artery disease
(CAD).[9] We previously described VCAM-1 to be strongly upregulated in the hearts of mice
with coxsackie virus-induced cardiomyopathy. Accordingly, patients with virus-induced DCM
showed high expression of cardiac VCAM-1 (cVCAM-1) when compared to patients with
non-inflammatory DCM, indicating that enhanced cVCAM-1 expression suggests a possible
inflammatory etiology of DCM.[10] The role of sVCAM-1 as a biomarker for disease severity
has not yet been defined for inflammatory heart diseases.
In this study we investigated the plasma levels of sVCAM-1 and studied the correlation
between disease activity and cardiac dysfunction in the mouse model of experimental autoim-
mune myocarditis (EAM).
Material and Methods
Immunization and Treatment Protocols
Six- to 8-week old male BALB/cmice (Charles River, Sulzfeld, Germany) were immunized by
subcutaneous injection of 200 μg heart-specific myosin-alpha heavy chain peptide (αMyHC;
Ac-RSLKLMATLFSTYASADR-OH; CASLO, Lyngby, Denmark) together with complete
Freund`s adjuvant (CFA; BD BIOSCIENCES, Heidelberg, Germany) on days 0 and 7 as previ-
ously described.[11] Sham mice were immunized on days 0 and 7 with CFA only. This study
was carried out in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Regierung von Oberbayern. The protocol was approved by
the Committee on the Ethics of Animal Experiments of the Regierung von Oberbayern (Permit
Number: GZ 55.2-1-54-2531-75-11). Mice were closely monitored throughout the experi-
ments. None of the animals utilized for this work needed to be euthanized due to severe illness
or died prior to the experimental endpoint. As indicated below, micro-PET was conducted
under isoflurane anesthesia.
ELISA
Proteins were extracted from hearts of immunized mice and healthy controls. After digestion
in 0.1% collagenase for 45 minutes, cells were lysed by ultrasonic pulse echo instrument.
cVCAM-1, interleukin-6 (IL-6) and transforming growth factor-β (TGF-β) proteins were
quantified using commercially available kits (VCAM-1: RayBiotech, Norcross, GA, Cat#
ELM-VCAM1-001; IL-6: Cat#M6000B, TGF-β: Cat#MB100B, R&D Systems, Minneapolis,
MN) according to the manufacturer’s instructions. For cVCAM-1, each value represents a
pooled analysis of two hearts. sVCAM-1 (R&D Systems, Minneapolis, MN, Cat# MVC00, and
RayBiotech, Norcross, GA, Cat# ELM-VCAM1-001) was quantified in plasma of immunized
sVCAM-1 in EAM
PLOSONE | DOI:10.1371/journal.pone.0158299 August 8, 2016 2 / 9
mice, sham immunized mice and healthy controls according to the manufacturer’s instruc-
tions. For both cardiac and soluble proteins, values represent mean of 2 consecutive
measurements.
Histology
Hearts were removed, fixed in paraffin and stained with hematoxylin/eosin to assess acute infil-
tration (day 21). Inflammation was evaluated semiquantitatively using the EAM severity score
(0, no inflammatory, infiltrates; 1, small foci of inflammatory cells between, myocytes; 2, larger
foci of 100 inflammatory cells; 3,>10% of a cross section involved; and 4,>30% of a cross sec-
tion involved) as previously described.[12]
In vivo cardiac PET imaging
PET scans were performed on day 49 using a dedicated small-animal PET scanner (Inveon
Dedicated PET, Preclinical Solutions, Siemens Healthcare Molecular Imaging, Knoxville, TN)
as described previously.[13] Briefly, mice were anesthetized with isoflurane (1.5%) delivered
via a face mask and were scanned in prone position. Fluorodeoxyglucose F 18 (FDG) was
injected at a dosage of 23+/-3 MBq in a volume of approximately 100μl via a tail vein catheter.
Data were processed with the Inveon Acquisition Workplace (Siemens Medical Solutions,
Knoxville, TN).
Statistical analysis
Data are shown as mean ± standard error of mean (SEM). Data were evaluated for normal dis-
tribution by the Anderson-Darling-Test. Comparison of>2 groups was conducted using one-
way ANOVA followed by Tukey`s post-hoc test.
Values of p< 0.05 were considered statistically significant. Correlations were evaluated
using Spearman correlation coefficient. Data were analysed using SPSS software.
Results
Cardiac and soluble VCAM-1 were elevated during EAM
The expression of VCAM-1 was previously shown to be substantially elevated in cardiac tissue
of patients with virus-induced DCM compared to patients without evidence of viral or inflam-
matory etiology of DCM.[10] To study the role of sVCAM-1 as a biomarker for disease severity
and progression, we used the EAMmodel in which cardiac inflammation was induced by
immunizing mice with αMyHC together with CFA. To investigate whether cVCAM-1 expres-
sion was increased in the EAMmodel, we performed ELISA in lysed cardiac tissue of immu-
nized mice. cVCAM-1 expression was significantly increased during the acute phase of the
disease at day 14 (p< 0.031, beginning of acute inflammation) as well as at the chronic stages
at day 49 (p<0.010) and day 77 (p< 0.004) compared to baseline conditions at day 0 (Fig 1A).
Comparison of baseline conditions with day 21 (peak of inflammation) almost reached signifi-
cance (p = 0.166). To determine elevated sVCAM-1 plasma levels during EAM, we performed
ELISA again at acute and chronic stages of the disease. In line with findings in the cardiac tis-
sue, significantly elevated sVCAM-1 levels were observed at day 14 (p = 0.014), day 21
(p = 0.032), day 49 (p = 0.003) and day 77 (p< 0.001) compared to baseline conditions at day
0 (Fig 1B). Sham treated mice did not show elevated sVCAM-1 levels at day 21 when compared
to baseline conditions at d0 (data not shown). These findings indicate elevated cVCAM-1
expression in cardiac tissue as well as elevated sVCAM-1 plasma levels during EAM.
sVCAM-1 in EAM
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sVCAM-1 plasma levels did not correlate with infiltration of leukocytes
or inflammatory and pro-fibrotic cytokines during EAM at peak of
inflammation
Next, we analyzed whether sVCAM-1 plasma levels would correlate with infiltration of leuko-
cytes and disease severity during EAM as it was shown for SLE[7] and RA.[6] To evaluate leu-
kocyte infiltration into the cardiac tissue during EAM, histological analysis of hearts from
immunized mice at day 21 was conducted (peak of inflammation). The degree of leukocyte infil-
tration was determined semi-quantitatively in H&E stained cardiac cross sections using the EAM
score. However, no correlation of sVCAM-1 with the severity of leukocyte infiltration was
observed (r = 0.325, p = 0.394, Fig 2A). Accordingly, sVCAM-1 plasma levels did not correlate
with the expression of the inflammatory marker IL-6 (r = -0.300, p = 0.433, Fig 2B) or the pro-
fibrotic marker TGFβ (r = -0.394, p = 0.260, Fig 2B) analyzed in the cardiac tissue by ELISA.
sVCAM-1 plasma levels correlated with heart/body weight ratios at
different time points
Heart/body weight ratio is frequently used to depict cardiac dilation in the chronic stage of EAM.
[11, 14, 15] We analyzed heart/body weight ratios in immunized mice at chronic stages of EAM
(day 49 and day 77). Statistical analysis revealed correlation of sVCAM-1 with heart/body weight
ratios at day 49 (r = 0.818, p = 0.001, Fig 3A) as well as day 77 (r = 0.661, p = 0.038, Fig 3B) indi-
cating a positive correlation of sVCAM-1 with the grade of cardiac dilation.
sVCAM-1 plasma levels showed a trend but no significant correlation
with cardiac size and function at chronic stages of disease
To verify these findings we performed micro-PET analyzing cardiac end-diastolic volume and
cardiac function parameters (Fig 4A and 4B) at day 49. As shown previously, micro-PET allows
Fig 1. Cardiac and soluble VCAM-1 levels were elevated during EAM. (A) ELISA of EAM hearts revealed a distinct upregulation of
cVCAM-1 at different time points, especially at the beginning of leukocyte infiltration (~ day 14) and at chronic stages of disease. (B)
Accordingly, quantification of plasma levels of VCAM-1 showed a significant augmentation at all time points. n = 3–9 for cVCAM-1 (n = 3
for day 0, n = 9 for day 14, n = 7 for day 21, n = 6 for day 49 and day 77, each value representing a pooled analysis of 2 hearts), n = 6–12
for sVCAM-1 (n = 6 for day 0, n = 11 for day 14, n = 7 for day 21, n = 12 for day 49 and day 77). * = p < 0.05; ** = p < 0.01, *** =
p < 0.001, n.d. = not detectable.
doi:10.1371/journal.pone.0158299.g001
sVCAM-1 in EAM
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precise and reproducible evaluation of cardiac size and cardiac function in mice.[13] However,
we found no correlation of sVCAM-1 with end-diastolic volume at day 49 (r = 0.036,
p = 0.939, Fig 4B) and could therefore not confirm our results on cardiac dilation. Finally,
Fig 2. sVCAM-1 did not correlate with the grade of inflammation or pro-inflammatory or pro-fibrotic cytokine levels. (A) Image shows
representative tissue section at day 21. sVCAM-1 did not correlate with grade of acute infiltration semi-quantitatively assessed using the EAM
score. (B) Accordingly, the pro-inflammatory cytokine IL-6, which is critically involved in the pathogenesis of myocarditis, showed no correlation as
well as the pro-fibrotic cytokine TGF-β. n = 9 for EAM score and IL-6; n = 10 for TGF-β. Bar represents 1 mm in the overview and 100 μm in the
magnified image.
doi:10.1371/journal.pone.0158299.g002
Fig 3. Heart/body weight ratio showed correlation with sVCAM-1 at different time points. (A) At day 49 (r = 0.818; p = 0.001) as
well as at (B) day 77 (r = 0.661; p = 0.038) of disease, sVCAM-1 showed a significant correlation with heart/body weight ratio which
reflects cardiac dilation at the chronic stage of disease. n = 12 for day 49, n = 10 for day 77.
doi:10.1371/journal.pone.0158299.g003
sVCAM-1 in EAM
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ejection fraction (r = -0.468, p = 0.289, Fig 4B) and stroke volume index (r = -0.571, p = 0.180,
Fig 4B) showed a moderate but not significant correlation with sVCAM-1 levels.
Discussion
In this study we evaluated the role of sVCAM-1 as a biomarker in myocarditis in EAM, a
model of myocarditis and DCMi.[16] Recent findings indicate that DCM arises from chronic
ongoing inflammation due to viral persistence or chronic autoimmune processes.[17] Lately,
high adiponectin levels have been shown to predict favourable outcome in patients with myo-
carditis.[16] Nevertheless, to date, no biomarker reliably reveals the diagnosis and/or depicts
the severity of myocarditis at various stages of the disease.
We showed that in EAM, cVCAM-1 is strongly upregulated in the heart during acute and
chronic stages of the disease. Our results are in line with previous findings of Eriksson et al.[18]
in the EAMmodel and our previous findings in the animal model of coxsackie virus-induced
Fig 4. micro-PET could not verify correlation of sVCAM-1 with the grade of dilation or cardiac function. (A) Representative image of short
and long axis view acquired with micro-PET at the end-diastolic and end-systolic period respectively. (B) EDV as a marker of cardiac dilation did
not significantly correlate with sVCAM-1 levels. Cardiac function parameters LVEF and SVI showed a moderate yet not significant correlation at
day 49. EDV = end-diastolic volume; LVEF = left ventricular ejection fraction; SVI = stroke volume index. n = 7.
doi:10.1371/journal.pone.0158299.g004
sVCAM-1 in EAM
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cardiomyopathy.[10] Our results indicate that upregulation of cVCAM-1 is not restricted to
viral infection of the heart but a feature of inflammation regardless of the underlying cause.
According to enhanced cardiac expression, we showed for the first time that sVCAM-1 was ele-
vated in EAM throughout the disease. To evaluate whether sVCAM-1 could function as a bio-
marker for the severity of EAM, we correlated sVCAM-1 levels with readouts for cardiac
inflammation.
The EAM score is a widely accepted method to semi-quantitatively assess cardiac inflamma-
tion by analyzing leukocyte infiltration during the acute stage (day 21).[11, 19–21] However,
no correlation could be detected between sVCAM-1 levels and grade of leukocyte infiltration
assessed by EAM score at the peak of inflammation.
We next assessed the correlation of sVCAM-1 with the cardiac expression of the pro-
inflammatory cytokine IL-6 and the pro-fibrotic cytokine TGF-β. IL-6 is a pro-inflamma-
tory cytokine critically involved in the pathogenesis of myocarditis. Immunized IL-6-defi-
cient mice showed a reduced cardiac expression of adhesion molecules intercellular cell
adhesion molecule-1 (ICAM-1) and VCAM-1, reduced antibody production, and reduced
activity of auto-reactive CD4+ helper cells, indicating a reduced susceptibility to EAM.[18]
Furthermore, IL-6 was shown to critically influence Th-17 differentiation, which does not
only affect disease initiation[22] but also the progression to dilated cardiomyopathy.[19]
TGF-β has been shown to be crucial for cardiac fibrosis as it promotes differentiation of
heart-infiltrating Prominin-1+ progenitor cells to cardiac fibroblasts.[11] However,
sVCAM-1 did not show a correlation with cardiac IL-6 or cardiac TGF-β at the peak of
inflammation.
We next examined heart/body weight ratios at the chronic stage. Increased heart/body
weight ratio at the chronic stage of EAM depicts cardiac dilation.[11, 15] Interestingly,
sVCAM-1 showed a statistically significant correlation with heart/body weight ratios at day 49
and day 77, indicating a correlation of sVCAM-1 with the grade of dilation at the chronic
stage. To verify these findings, we investigated mice by micro-PET and evaluated end-diastolic
volumes. Micro-PET is a dedicated small animal imaging device which has been previously
used for the evaluation of cardiac function and dilation in a mouse model of myocardial infarc-
tion.[13] Micro-PET analysis of end diastolic volumes did not verify a correlation of sVCAM-1
with the grade of dilation in mice with EAM. We finally evaluated cardiac function parameters
including LVEF and SVI. Despite a clear deterioration of EAMmice in comparison to healthy
controls of a previous study,[23] cardiac function parameters did show a moderate but not sig-
nificant correlation with sVCAM-1.
Our findings indicate that sVCAM-1 could serve as a marker for inflammatory dilated car-
diomyopathy. However, although we observed some positive correlation of cardiac dilation
and sVCAM-1, there is no clear evidence that the amount of sVCAM-1 in the plasma positively
correlates with the severity of myocarditis at the acute or chronic stage.
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